Osher LLI at FAU Announces Spring Course Schedule
The Osher Lifelong Learning Institute at 秘密研究院 in Jupiter has announced its course offerings for the spring semester, which begins Tuesday, March 14.
Could This Toothpaste Prevent a Heart Attack or Stroke?
A study by FAU and collaborators shows Plaque HD庐, the first toothpaste that identifies plaque so that it can be removed with directed brushing, significantly reduces inflammation throughout the body.
FAU to Celebrate 2020 President's Gala
秘密研究院 is set to celebrate its ninth annual gala on Saturday, April 4 at 7 p.m. in the Martin F. and Jane Greenberg Foundation Tower of FAU Stadium at its Boca Raton campus.
FAU Research Explores Regulatory Ambiguity in Bitcoin Market
Regulatory ambiguity surrounding the peer-to-peer virtual currency continues to discourage entrepreneurial activity by increasing risk and the costs of compliance.
FAU Recognized as 'Gold' Military Friendly庐 University
FAU has earned the 2020-2021 Military Friendly庐 School "Gold Designation" for the first time, based on the expanding services and spaces offered by FAU's Military and Veterans Student Success Center.
Avron B. Fogelman Sports History Museum Opens at FAU
The Avron B. Fogelman Sports History Museum recently opened in the Schmidt Family Complex for Academic and Athletic Excellence.
Neighborhood Features and Genetic Risk Interact to Affect Cognition
A new FAU study is the first to examine how neighborhood environment affects cognition in older adults based on their genetic risk for Alzheimer's disease and dementia.
Osher Lifelong Learning Institute at FAU Presents Terry Virts
The Osher LLI at FAU in Jupiter will present a lecture by Terry Virts, on Wednesday, March 4 at 7 p.m.
'Super Tuesday Results: What They Mean for Election 2020'
The Osher Lifelong Learning Institute at 秘密研究院 in Boca Raton will present "Super Tuesday Results: What They Mean for Election 2020," a discussion and analysis
Researchers Challenge New Guidelines on Aspirin in Primary Prevention
New guidelines recommend aspirin use in primary prevention for people ages 40 to 70 years old who are at higher risk of a first cardiovascular event, but not for those over 70.